Stephen Whitehead, Chief Executive of the ABPI said:
"The practices revealed in the Daily Telegraph’s recent investigation on the sale of ‘specials’ medicines, if found to be true, are completely unacceptable and we condemn them in the strongest terms. We fully support the Department of Health’s investigation in to these practices.
"None of the companies referred to in the Telegraph’s investigation are members of the ABPI."
Notes to Editor
A ‘Special’ is an unlicensed medicine prescribed for an individual patient when a suitable licensed medicine cannot be found to meet a specific need. They account for just one per cent of all prescriptions written in the UK and because of their unique nature the way they are regulated, priced and prescribed are very different from all other prescription medicines.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064